3-(1H-吡咯-1-基)苯胺 | 89353-42-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯
• 中文名称: 3-(1H-吡咯-1-基)苯胺
• 中文别名: 三异丙基硅基乙炔
• 英文名称: 3-(1H-pyrrol-1-yl)aniline
• 英文别名: 1-(3-aminophenyl)pyrrole；3-pyrrol-1-ylaniline
• CAS: 89353-42-4
• 化学式: C₁₀H₁₀N₂
• mdl: MFCD03407309
• 分子量: 158.203
• InChiKey: PJGDCPOPSNUYHC-UHFFFAOYSA-N

物化性质

• 熔点：
  43 °C
• 溶解度：
  18.2 [ug/mL]

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  31
• 氢给体数：
  1
• 氢受体数：
  1

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi
• 安全说明：
  S26,S36/37/39,S37/39
• 危险类别码：
  R36/37/38
• 海关编码：
  2933990090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335

SDS

Name:	3-(1H-Pyrrol-1-yl)aniline 97% Material Safety Data Sheet
Synonym:
CAS:	89353-42-4

Section 1 - Chemical Product MSDS Name:3-(1H-Pyrrol-1-yl)aniline 97% Material Safety Data Sheet
Synonym:

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
89353-42-4	3-(1H-Pyrrol-1-yl)aniline		unlisted

Hazard Symbols: XI
Risk Phrases: 36/37/38

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Irritating to eyes, respiratory system and skin.
Potential Health Effects
Eye:
Causes eye irritation.
Skin:
Causes skin irritation. May be harmful if absorbed through the skin.
Ingestion:
May cause irritation of the digestive tract. May be harmful if swallowed.
Inhalation:
Causes respiratory tract irritation. May be harmful if inhaled.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

---

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 89353-42-4: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Not available.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Powder
Color: beige
Odor: mild odor - faint odor
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 43 - 45 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C10H10N2
Molecular Weight: 158.2

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Strong oxidizing agents.
Hazardous Decomposition Products:
Nitrogen oxides, carbon monoxide, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 89353-42-4 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
3-(1H-Pyrrol-1-yl)aniline - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
No information available.
IMO
No information available.
RID/ADR
No information available.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XI
Risk Phrases:
R 36/37/38 Irritating to eyes, respiratory system
and skin.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 37/39 Wear suitable gloves and eye/face
protection.
WGK (Water Danger/Protection)
CAS# 89353-42-4: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 89353-42-4 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 89353-42-4 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  3-(1H-吡咯-1-基)苯胺 在 sodium hydroxide 作用下， 以 二苯醚 、 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 35.5h， 生成 1-乙基-1,4-二氢-4-氧代-7-(1-吡咯基)喹啉-3-羧酸乙酯
  参考文献：
  名称：

  Corelli; Massa; Stefancich, Farmaco, Edizione Scientifica, 1984, vol. 39, # 2, p. 95 - 109

  摘要：

  DOI：
• 作为产物：
  描述：

  1-(3-硝基苯基)-1H-吡咯 在 palladium on activated charcoal 、 一水合肼 作用下， 以 乙醇 为溶剂， 反应 0.5h， 以82.1%的产率得到3-(1H-吡咯-1-基)苯胺
  参考文献：
  名称：

  新型取代苯甲酰胺类化合物及其药学上可接受的盐及制备方法和应用

  摘要：

  本发明涉及通式为Ⅰ所示的新型取代苯甲酰胺类化合物及其药学上可接受的盐及制备方法和应用。本发明还提供了含有它们的药物组合物，和体外和体内的抗肿瘤作用结果和急性毒性研究，本发明得到的抗肿瘤药物新型取代苯甲酰胺类化合物，具有更优良的抗肿瘤活性和安全性，可在治疗白血病、肺癌、结肠癌、卵巢癌及肾癌等肿瘤中的应用，因而治疗窗宽，所以在医药领域中作为抗肿瘤剂是非常有应用价值的。

  公开号：

  CN110372705A

文献信息

• [EN] INDOLE AMIDE DERIVATIVES AND RELATED COMPOUNDS FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES<br/>[FR] DÉRIVÉS D'INDOLAMIDE ET COMPOSÉS ASSOCIÉS DESTINÉS À ÊTRE UTILISÉS DANS LE TRAITEMENT DES MALADIES NEURODÉGÉNÉRATIVES
  申请人：UNIV LEUVEN KATH

  公开号：WO2010142801A1

  公开（公告）日：2010-12-16

  This invention provides novel compounds and the novel compounds for use as a medicine, more in particular for the prevention or treatment of neurodegenerative disorders, more specifically certain neurological disorders, such as disorders collectively known as tauopathies, and disorders characterised by cytotoxic α-synuclein amyloidogenesis. The present invention also relates to the use of said novel compounds for the manufacture of medicaments useful for treating such neurodegenerative disorders. The present invention further relates to pharmaceutical compositions including said novel compounds and to methods for the preparation of said novel compounds.

  本发明提供了新型化合物，以及这些新型化合物作为药物的使用，特别是用于预防或治疗神经退行性疾病，更具体地是一些神经系统疾病，例如统称为tauopathies的疾病，以及以细胞毒性α-突触核蛋白淀粉样蛋白生成为特征的疾病。本发明还涉及将所述新型化合物用于制造用于治疗此类神经退行性疾病的药物。本发明还涉及包括所述新型化合物的药物组合物，以及制备所述新型化合物的方法。
• [EN] NOVEL 4-AMINO-N-HYDROXY-BENZAMIDES AS HDAC INHIBITORS FOR THE TREATMENT OF CANCER<br/>[FR] NOUVEAUX 4-AMINO-N-HYDROXY-BENZAMIDES EN TANT QU'INHIBITEURS DE HDAC POUR LE TRAITEMENT DU CANCER
  申请人：HOFFMANN LA ROCHE

  公开号：WO2012098132A1

  公开（公告）日：2012-07-26

  The present invention provides hdac inhibitors of formula (I), or pharmaceutically acceptable salts, esters or stereoisomers thereof, wherein R1 to R4, A and Y have the meanings given herein, as well as methods for making those compounds and their use as medicament, in particular as medicament for the treatment of cancer.

  本发明提供了式(I)的HDAC抑制剂，或其药学上可接受的盐、酯或立体异构体，其中R1至R4、A和Y具有本文中给出的含义，以及制备这些化合物的方法以及它们作为药物的用途，特别是作为治疗癌症的药物。
• Ruthenium-Catalyzed Synthesis of Highly Substituted Pyrroles from 1-Vinylpropargyl Alcohols and Amines
  作者：Nora Thies、Martin Gerlach、Edgar Haak

  DOI：10.1002/ejoc.201300803

  日期：2013.11

  Ruthenium-catalyzed atom-economic transformations of 1-vinylpropargyl alcohols with amines leading to highly substituted pyrroles in a one-pot cascade process are reported. The allylation/cycloisomerization sequence is catalyzed by a single ruthenium(0) complex that contains a redox-coupled dienone ligand and can be extended by an additional [3,3] rearrangement. The environmentally benign reactions

  报道了钌催化的 1-乙烯基炔丙醇与胺的原子经济转化，导致在一锅级联过程中产生高度取代的吡咯。烯丙基化/环异构化序列由包含氧化还原偶联二烯酮配体的单个钌 (0) 络合物催化，并可通过额外的 [3,3] 重排进行扩展。环境友好的反应允许金属催化将廉价且易于获得的材料转化为高度官能化的吡咯，而水作为唯一的废物产物。
• Identification of novel plasminogen activator inhibitor-1 inhibitors with improved oral bioavailability: Structure optimization of N-acylanthranilic acid derivatives
  作者：Nagahisa Yamaoka、Kenji Murano、Hidehiko Kodama、Akihisa Maeda、Takashi Dan、Tetsuo Nakabayashi、Toshio Miyata、Kanji Meguro

  DOI：10.1016/j.bmcl.2017.11.016

  日期：2018.2

  compounds in which 5-chloroanthranilic acid was bound to a variety of highly lipophilic moieties with appropriate linkers was investigated. As the result it appeared that some of the derivatives possessing aryl- or heteroaryl-substituted phenyl groups in the acyl chain had potent in vitro PAI-1 inhibitory activity. Oral absorbability of typical compounds was also evaluated in rats, and compounds 40,

  通过对N-酰基-5-氯邻氨基苯甲酸衍生物的结构-活性关系研究发现了新型的具有显着改善的口服生物利用度的纤溶酶原激活物抑制剂-1（PAI-1）抑制剂。由于亲脂性N-酰基对于邻氨基苯甲酸衍生物强烈抑制PAI-1似乎很重要，因此研究了其中5-氯邻氨基苯甲酸与各种具有适当连接基的高度亲脂性部分结合的化合物的合成。结果表明，某些在酰基链上具有被芳基或杂芳基取代的苯基的衍生物具有有效的体外PAI-1抑制活性。还评估了大鼠中典型化合物的口服吸收能力，化合物40，55，60和76被选择具有相互不同的化学结构，用于进一步药理评价。
• Selective <i>N</i>-monomethylation of primary anilines with the controllable installation of <i>N</i>-CH₂D, <i>N</i>-CHD₂, and <i>N</i>-CD₃ units
  作者：Jing Meng、Hui-Min Xia、Ai-Qing Xu、Yi-Feng Wang、Zhijuan Wang、Feng-Lian Zhang

  DOI：10.1039/d0ob01054e

  日期：——

  The selective N-monomethylation of primary anilines with the controllable installation of N-CH₂D, N-CHD₂, and N-CD₃ units was realized by using the amine-borane/N,N-dimethylformamide (DMF) system as the methyl precursor.

  主要苯胺的选择性N-单甲基化通过使用胺硼烷/N,N-二甲基甲酰胺（DMF）体系作为甲基前体，实现了可控地安装N-CH2D、N-CHD2和N-CD3基团。